FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

PMA: P970038 · Supplement: S042 · Decision Oct 7, 2020
Classifications
1
FEI Numbers
15
Registration Numbers
15

Basic Information

Device Name
Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions
Trade Name
Access Hybritech Free PSA Reagents on the Access Immunoassay Systems
PMA Number
P970038
Supplement Number
S042
Device Class
FDA Class 3
Product Code
MTG
Generic Name
Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions
Medical Specialty
Unknown
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
October 7, 2020
Date Received
June 23, 2020
Supplement Type
Real-Time Process
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

Approval for modification to the Access 2 Immunoassay System Pipettor gantry.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MTG Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions